

ADVERSE DRUG REACTIONS, INCLUDING SJS, TEN

## **ANTI-PROGRAMMED CELL DEATH-1 THERAPY ASSOCIATED BULLOUS DISORDERS: A SYSTEMATIC REVIEW OF THE LITERATURE AND CLASSIFICATION**

*Cathy Y Zhao<sup>(1)</sup> - Shelley Je Hwang<sup>(1)</sup> - Germana Consuegra<sup>(1)</sup> - Shaun Chou<sup>(2)</sup> - Pablo Fernandez-penas<sup>(1)</sup>*

*Centre For Translational Skin Research, Westmead Hospital, University Of Sydney, Australia, Sydney<sup>(1)</sup> - Department Of Pathology, Westmead Hospital, Australia, Sydney<sup>(2)</sup>*

**Background:** Bullous disorders are rare adverse events associated with anti-Programmed cell death-1 therapy (anti-PD1). We present 2 new cases of bullous disorders under anti-PD1 and a systematic review of the literature regarding the presentation and pathogenesis of bullous disorders under anti-PD1.

**Methods:** A comprehensive systematic review of the literature was completed utilizing MEDLINE, Embase, PubMed and LILACS databases.

**Results:** We identified 29 cases of bullous disorders under anti-PD1, including our 2 new cases. This includes 18 cases of bullous pemphigoid (BP), 5 cases of toxic epidermal necrolysis (TEN)/Stevens-Johnson Syndrome (SJS) spectrum, 1 case of erythema multiforme (EM), 4 cases of bullous lichenoid reactions and 1 case of vesiculobullous eczema. In BP, blistering occurred by a median of 23 weeks after anti-PD1 initiation and is often preceded by a prodrome, which lasts for a median of 9.5 weeks. Limbs and trunk were the most frequently involved body sites. Most cases (76%) achieved remission. TEN/SJS/EM: Blistering was usually preceded by a prodrome of interface dermatitis that lasted for a median of 1.5 weeks. Most cases (80%) died either from TEN/SJS or disease progression.

**Conclusion:** Bullous disorders under anti-PD1 may be classified clinically as BP, SJS/TEN/EM, bullous lichenoid reactions and vesiculobullous eczema, and histologically by intraepidermal splitting and subepidermal splitting. BP is usually preceded by a pruritic eruption and has a relatively good prognosis. SJS/TEN is usually preceded by a maculopapular eruption and has a very poor prognosis.